Quest Diagnostics (DGX) PT Lowered to $100 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Quest Diagnostics (DGX) Reports Election of Denise Morrison to Board
February 19, 2019 5:06 PM ESTQuest Diagnostics (NYSE: DGX) today announced that its Board of Directors has elected Denise M. Morrison to serve as a director, effective February 18, 2019. Including Ms. Morrison, the company's Board has 11 members.
Ms. Morrison served as President and Chief Executive Officer of Campbell... More
Quest Diagnostics (DGX) PT Lowered to $98 at Morgan Stanley
February 15, 2019 8:06 AM ESTMorgan Stanley analyst Ricky Goldwasser lowered the price target on Quest Diagnostics (NYSE: DGX) to $98.00 (from $101.00) while maintaining a Overweight rating.
... MoreQuest Diagnostics (DGX) PT Raised to $91 at UBS
February 15, 2019 7:43 AM ESTUBS raised its price target on Quest Diagnostics (NYSE: DGX) to $91.00 (from $90.00) while maintaining a Neutral rating.
... MoreQuest Diagnostics (DGX) PT Lowered to $93 at Citi
February 15, 2019 7:08 AM ESTCiti analyst Ralph Giacobbe lowered the price target on Quest Diagnostics (NYSE: DGX) to $93.00 (from $95.00) while maintaining a Neutral rating.
... MoreQuest Diagnostics (DGX) Misses Q4 EPS by 3c, Revenues; Offers FY19 EPS/Revenue Guidance Below Consensus
February 14, 2019 6:50 AM ESTQuest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.36, $0.03 worse than the analyst estimate of $1.39. Revenue for the quarter came in at $1.84 billion versus the consensus estimate of $1.88 billion.
"In 2018 we grew revenues, adjusted earnings and cash from operations despite some challenges in the... More
